Overweight , Obesity study: ALV-100
Official title Study to Assess the Effect and Safety of ALV-100 on Maintenance of Weight Loss
ClinicalTrials.gov ID: NCT07837973
What this study is testing
What is ALV-100?
An investigational oral drug being studied as a potential treatment for overweight and obesity.
Plain-language explanation of the investigational treatment. It is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- The study aims to find out whether ALV-100 is safe and can maintain weight loss in people who have already lost weight with incretin‑based medicines.
- Who it's for
- Adults who are overweight or obese and have already lost at least 10% of their body weight using incretin‑based therapy.
- What's involved
- Participants will take the study drug ALV-100 and undergo regular safety checks and other study visits.
- Phase 2: a mid-size study of how well it works
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 75
You may be able to join if
- Key 1. Adult male and female participants, aged ≥18 to ≤75
- BMI ≥23 kg/m2 at screening.
- Has been treated with incretin-based therapy for weight management at a stable dose for at least 3 continuous months prior to screening.
- Tolerating incretin-based therapy at the discretion of the investigator
- WL of at least 10% while on incretin-based therapy and with stable BW for at least 3 months prior to screening.
You likely can't join if
- Lifetime history of Type 1 or Type 2 diabetes
- Prior obesity treatment with surgery or a weight loss device.
- Obesity caused by known endocrinologic disorders or by known congenital or acquired hypothalamic disease or monogenetic or syndromic forms of obesity.
- Current or history of (within 3 months prior to screening) treatment with medications that may cause significant weight gain.
- Family or personal history of MTC or MEN 2
- Presence or history of malignant neoplasms within the past 5 years prior to screening
See the full eligibility criteria
- Key 1. Adult male and female participants, aged ≥18 to ≤75
- BMI ≥23 kg/m2 at screening.
- Has been treated with incretin-based therapy for weight management at a stable dose for at least 3 continuous months prior to screening.
- Tolerating incretin-based therapy at the discretion of the investigator
- WL of at least 10% while on incretin-based therapy and with stable BW for at least 3 months prior to screening.
- Willing to maintain their current general diet and physical activity regimen throughout the study. Key
- Lifetime history of Type 1 or Type 2 diabetes
- Prior obesity treatment with surgery or a weight loss device.
- Obesity caused by known endocrinologic disorders or by known congenital or acquired hypothalamic disease or monogenetic or syndromic forms of obesity.
- Current or history of (within 3 months prior to screening) treatment with medications that may cause significant weight gain.
- Family or personal history of MTC or MEN 2
- Presence or history of malignant neoplasms within the past 5 years prior to screening
The study team makes the final eligibility decision.
Where it is enrolling
- Birmingham, Alabama, United States
- Sun City, Arizona, United States
- Tempe, Arizona, United States
- Oceanside, California, United States
- Bradenton, Florida, United States
- Doral, Florida, United States
- Orlando, Florida, United States
- Woodstock, Georgia, United States
- Champaign, Illinois, United States
- Gretna, Louisiana, United States
- Farmington Hills, Michigan, United States
- New York, New York, United States
- Wilmington, North Carolina, United States
- Oklahoma City, Oklahoma, United States
- Nashville, Tennessee, United States
- Irving, Texas, United States
- San Antonio, Texas, United States
- Tomball, Texas, United States
- South Jordan, Utah, United States
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part, but confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years to 75 years. The study team makes the final eligibility decision.
Where is this trial taking place?
This study is enrolling now at Birmingham, Alabama, United States; Sun City, Arizona, United States; Tempe, Arizona, United States; Oceanside, California, United States; Bradenton, Florida, United States; Doral, Florida, United States and 13 more locations. Enter your location above to see the nearest enrolling site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool that is independent of the study sponsor. Details come from ClinicalTrials.gov. The study team decides eligibility, and your own doctor gives medical advice.